July 06, 2009
Alimta approved for nonsquamous non-small cell lung cancer (NSCLC) maintenance therapy
Alimta is already indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous NSCLC or for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. Alimta is also indicated as monotherapy for the treatment of locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy.
For more information call (800) 545-5979 or visit www.alimta.com.